Compare TFSL & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | TFSL | GPCR |
|---|---|---|
| Founded | 1938 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.8B |
| IPO Year | 2006 | 2023 |
| Metric | TFSL | GPCR |
|---|---|---|
| Price | $16.31 | $20.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 16 |
| Target Price | $18.25 | ★ $105.78 |
| AVG Volume (30 Days) | 685.4K | ★ 1.2M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 7.78% | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.17 | N/A |
| Revenue Next Year | $7.60 | N/A |
| P/E Ratio | $60.52 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.91 | $21.55 |
| 52 Week High | $19.49 | $94.90 |
| Indicator | TFSL | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 41.48 | 13.66 |
| Support Level | $16.02 | N/A |
| Resistance Level | $16.96 | $56.63 |
| Average True Range (ATR) | 0.27 | 1.58 |
| MACD | 0.02 | -0.28 |
| Stochastic Oscillator | 37.69 | 2.01 |
TFS Financial Corp is the holding company for the Third Federal Savings and Loan Association of Cleveland. The company's ownership in the savings and loan association is its primary business activity. The association's principal business consists of originating and servicing residential real estate mortgage loans and attracting retail savings deposits. It does so by offering products with competitive rates and yields. The company also operates Third Capital, a wholly owned subsidiary that serves as a holding company or as an investor in vehicles such as private equity funds. Third Capital has interests in lease transactions of commercial buildings, title agencies providing escrow and settlement services, and reinsurance of private mortgage insurance on residential loans.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.